- By Duska Anastasijevic
New vaccine platform invented by Mayo enters COVID-19 clinical trial
A novel single-cycle adenovirus vaccine platform developed by Mayo Clinic will be used to target multiple infectious diseases and cancer indications, beginning with a phase 1 clinical study using the platform as a vaccine for COVID-19.
Developed to enhance the expression of target antigens, the single-cycle adenovirus platform is under investigation for its ability to amplify immune responses. In contrast to replication-defective vaccines, the single-cycle vector amplifies immune response potential based on preclinical trials.
“The single-cycle adenovirus vaccine engine amplifies SARS-CoV-2 spike antigen production nearly 100-fold when compared to matched replication-defective adenoviruses,” says Michael Barry, Ph.D., the director of Mayo Clinic's Vector and Vaccine Engineering Laboratory and co-developer of the platform. “Single-cycle is particularly potent as a nasal vaccine, fighting SARS at its site of entry.”
The single-cycle adenovirus vaccine platform was licensed to Tetherex Pharmaceuticals, Inc., a privately-held biopharmaceutical company, which announced the start of the Phase 1 trial.
Read more about this adenovirus platform and Dr. Barry’s work here.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
Learn more about: Tracking COVID-19 and COVID-19 trends.